Page 61 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat

肝癌合併門靜脈高壓病患接受標靶加上免疫治療成功案例－病例報告

樊修龍 謝宗保
1,2
1
1 三軍總醫院外科部一般外科 移植外科
2

Successful combined therapy with target therapy and immunotherapy in HCC patient with
main portal vein thrombosis - a case report

Hsiu-Lung Fan , Chung-Bao Hsieh
1
1,2
1 Division of General Surgery and Division of Transplant Surgery, Department of Surgery,
2
Tri-Service General Hospital, Taipei, Taiwan

Purpose:
Immunotherapy for hepatocellular carcinoma (HCC) has become one of treatments in
advanced HCC. Combined therapy with target therapy and immunotherapy is under

investigation in many clinical trials. We reported a 60 years-old male with the history of
HBV presented with tea-color urine for days. CT and MRI revealed multiple hepatic
tumors over bilateral lobes of liver with right, left, and main portal vein thrombosis. AFP
was 109.3 ng/mL before treatment. The patient received radiotherapy for main portal vein
thrombosis. Lenvatinib 10mg was prescribed every day. Immunotherapy with Nivolumab

200mg were prescribed every 3 weeks. Cell therapy with cytokine-induced killer cell was
prescribed every week. After 3 months, AFP returned to normal range level(3.08ng/mL).
Main portal vein thrombosis and left portal vein thrombosis resolved. In conclusion,

combination therapy with target therapy, immunotherapy and cell therapy has potential
treatment benefit in advanced hepatocellular carcinoma.